Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96NT5

UPID:
PCFT_HUMAN

ALTERNATIVE NAMES:
Heme carrier protein 1; PCFT/HCP1; Solute carrier family 46 member 1

ALTERNATIVE UPACC:
Q96NT5; Q1HE20; Q86T92; Q8TEG3; Q96FL0

BACKGROUND:
PCFT/HCP1, also known as Solute Carrier Family 46 Member 1, plays a crucial role in folate homeostasis by facilitating the absorption of folates and their transport into the central nervous system. It operates effectively at acidic pH and is involved in the transport of antifolate drugs used in cancer and autoimmune disease treatments. Additionally, PCFT/HCP1 acts as a heme carrier, essential for importing heme in various organs.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of PCFT/HCP1 could open doors to potential therapeutic strategies. Its involvement in Hereditary folate malabsorption, characterized by impaired folate absorption and severe neurological defects, underscores the protein's significance. Effective targeting of PCFT/HCP1 could lead to breakthrough treatments for this disorder and enhance the efficacy of antifolate drugs in cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.